share_log

Avadel Announces Publications In CNS Drugs Supplement Titled "A New Dawn In The Management Of Narcolepsy" Highlighting Key Clinical Issues For People With Narcolepsy And Their Clinicians

Benzinga ·  Mar 25 12:10

Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a CNS Drugs supplement titled "A New Dawn in the Management of Narcolepsy".

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 204

Recommended

Write a comment